Electra Therapeutics, Inc.
Electra Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California. It develops therapies aimed at signal regulatory proteins for immunological diseases and cancer. Its product candidate ELA026 is a monoclonal antibody designed to remove pathological immune cells for the treatment of secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition.
No enriched coverage for $ETRA in the last 7 days.
GORDON CARL L purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05.
ORBIMED ADVISORS LLC purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).
H.C. Wainwright initiated coverage on Electra Therapeutics (ETRA) with a buy rating and $30 price target, citing clinical progress and financial flexibility. The stock trades near its 52-week low at $8.71. Multiple analysts rate ETRA positively, highlighting its lead drug candidate, ipsoprubart, in trials for hemophagocytic lymphohistiocytosis. The company's upcoming IPO is expected to price above its $14-$16 range.
Recent ETRA coverage spans financial news and insider activity.
In the last 30 days, ETRA insiders filed 10 SEC Form 4 transactions — 10 purchases ($3.6M) and no sales. The most active reporter was ORBIMED ADVISORS LLC with 10 filings.
Significant insider purchase suggests confidence in near-term prospects.
Insider purchase suggests confidence in Electra Therapeutics, may support price.
Analyst initiation and a high price target suggest potential upside.
New coverage could spark interest in the biotech's pipeline.
Positive analyst initiation likely drives buying pressure.
AlphAI scores every news story that mentions ETRA with an AI model for sentiment and relevance, and aggregates insider trades from Electra Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GORDON CARL L purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05.
ORBIMED ADVISORS LLC purchased 472,571 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at an average of $7.63 ($7.07–$7.88, $3.61M total) across 10 trades over 2026-11-03 to 2026-11-05. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).
H.C. Wainwright initiated coverage on Electra Therapeutics (ETRA) with a buy rating and $30 price target, citing clinical progress and financial flexibility. The stock trades near its 52-week low at $8.71. Multiple analysts rate ETRA positively, highlighting its lead drug candidate, ipsoprubart, in trials for hemophagocytic lymphohistiocytosis. The company's upcoming IPO is expected to price above its $14-$16 range.
Analysts made several calls on Wall Street, including upgrades for Block (SQ), Tesla (TSLA), and IBM (IBM), among others. BMO upgraded Block to outperform, citing positive catalysts. Morgan Stanley raised Tesla's price target to $410. Goldman Sachs reiterated IBM as a buy. Other notable mentions include upgrades for Kohl's (KSS) and downgrades for Netflix (NFLX).
JPMorgan initiated coverage on Electra (NASDAQ:ETRA) with an Overweight rating and a $36.00 price target, implying 300% upside from the current $9.05. The firm's thesis is based on the potential of ipsoprubart, a drug in Phase 2/3 trials for secondary hemophagocytic lymphohistiocytosis (sHLH). Electra is preparing for an IPO priced between $14 and $16, with strong institutional demand.
TD Cowen initiated coverage on Electra (NASDAQ:ETRA) with a buy rating, highlighting the potential of its drug candidate ipsoprubart for treating secondary hemophagocytic lymphohistiocytosis. The company has a market cap of $585 million and has seen a 30% year-to-date decline. Analysts estimate $3.8 billion in sales by 2035, excluding upside from ELA822. Electra is preparing for an IPO, with significant investor demand.
OrbiMed Advisors disclosed an 11.0% stake in Electra Therapeutics (ETRA) following its IPO. The firm acquired the shares for investment, not control, and agreed to a 180-day lock-up period. OrbiMed is a healthcare-focused investment advisor.
GORDON CARL L purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21.
Electra Therapeutics (ETRA) reports that OrbiMed funds converted preferred shares into 5.55M common shares and purchased 1.33M additional shares at $15 each during its IPO on September 21, 2026. OrbiMed Advisors, a director and 10% owner, disclaims beneficial ownership except for pecuniary interest.
ORBIMED ADVISORS LLC purchased 1,333,333 indirectly-held shares of Electra Therapeutics, Inc. (ETRA) at $15.00 ($20.00M total) across 2 trades on 2026-09-21. Filed jointly with OrbiMed Capital GP VII LLC (Director) and OrbiMed Genesis GP LLC (Director).
